How review works
- Writer drafts content with sources cited inline.
- Editor reviews for clarity, reading level, and brand voice.
- Medical reviewer fact-checks every clinical claim against current evidence.
- Compliance check for FDA, CDSCO, and Drugs and Magic Remedies Act guidance.
- Accessibility check (alt text, heading order, contrast).
- Publication with reviewer byline and last-reviewed date visible.
- Re-review at minimum every 12 months.
Review board composition
Lead Reviewer — Prostate Cancer
Medical Oncologist
Senior medical oncologist with extensive experience in advanced prostate cancer management and theranostics. Reviews all Lu-177 PSMA therapy-related content.
No financial relationships with Lu-177 therapy manufacturers in the past 24 months.
Lead Reviewer — Neuroendocrine Tumors
Medical Oncologist
Specialist in neuroendocrine tumor management with subspecialty in peptide receptor radionuclide therapy. Reviews all Lu-177 DOTATATE therapy-related content.
Discloses participation in NETTER-2 trial; no commercial relationships affecting editorial content.
Lead Reviewer — Procedures & Safety
Nuclear Medicine Physician
Nuclear medicine physician with extensive Lu-177 therapy administration experience. Specialist in radiation protection. Reviews procedural and radiation safety content.
No financial relationships disclosed.
Safety Reviewer
Radiation Safety Officer
Certified radiation safety officer with focus on therapeutic radionuclide handling and patient/family safety guidance.
No financial relationships disclosed.
Drug Information Reviewer
Oncology Pharmacist
Hospital pharmacist specializing in oncology and radiopharmaceutical preparation.
No financial relationships disclosed.
Lived-Experience Reviewer
Patient Advocate
Cancer survivor and patient advocate. Reviews content for clarity, empathy, and patient-perspective accuracy.
No financial relationships disclosed.
Conflict of interest disclosure
All reviewers disclose financial relationships annually, including:
- Industry consulting
- Stock holdings in healthcare companies
- Speaker fees
- Trial leadership or sponsorship
- Any other financial relationship with parties that could influence editorial content
Reviewers with conflicts of interest may be excluded from reviewing content directly related to their disclosures.
Reviewer compensation
Reviewers are compensated at flat per-page rates that are not contingent on recommendations. No reviewer is paid by any party with commercial interest in the content (no drug manufacturer payments, no center-by-recommendation arrangements).
How to suggest a reviewer
If you're a medical professional interested in joining our review board, or if you'd like to recommend someone, please contact us at connect@artofhealingcancer.com. We're always seeking to expand our reviewer pool.